Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T12:50:48.905Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T12:50:48.905Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
FORWARD PE RATIO
N/A
Braveheart Bio, Inc.
Market Cap
$1.51B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Braveheart Bio, Inc. (BRVE) | $1.51B | N/A |
| GH Research PLC (GHRS)vs › | $1.52B | N/A |
| Innoviva, Inc. (INVA)vs › | $1.52B | 8.53 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 51.14 |
| AnaptysBio, Inc. (ANAB)vs › | $1.46B | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 17.67 |
| Certara, Inc. (CERT)vs › | $1.57B | 29.56 |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.43B | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 32.82 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
